Human CA50 (CarbohydRate Antigen 50) ELISA Kit

A three-dimensional simulation model coupled with detailed chemical kinetics mechanism is applied to investigate a diesel engine fueled with directly injected methanol and pilot diesel. The diesel is injected before top dead center (TDC) to act as a pilot, and then methanol is also directly injected afterwards diesel injection as the main fuel. The effects of diesel and methanol injection timing on the combustion, performance, and emissions are investigated. The results show that: advanced diesel and methanol injections have higher in-cylinder pressure peak; and the in-cylinder pressure peak decreases with the increase of dwell. The ignition delay reduces first and then remains unchanged with the increase of dwell. 50% burn point (CA50) increases in a nearly linear way with the increase of dwell. There are four different combustion phenomena with varied dwell. Too small dwell leads to misfire or roar combustion, and too large dwell is detrimental to fuel economy. Advanced diesel and methanol injections contribute to lower equivalent indicated specific fuel consumption (EISFC) and soot emission, but lead to higher ringing intensity (RI) and nitrogen oxides (NOx) emission.

Olaparib is an oral poly AlP-ribose polymerase inhibitor with activity in germline BRCA1 and BRCA2 (BRCA1/2)-associated breast and ovarian cancers. There is no report about treatment with olaparib in BRCA1/2-mutated intrahepatic cholangiocarcinomas. This study is to observe the efficacy and safety of olaparib monotherapy in the refractory BRCA1/2-mutant intrahepatic cholangiocarcinoma (ICC) patient. The clinical record of a patient with BRCA2-mutated refractory advanced ICC treated with olaparib was analyzed. The patient was administered with olaparib (400 mg orally twice daily) and followed up for 11 months. The clinical tumor response was evaluated after 4 weeks of olaparib treatment, and then every 8 weeks (two treatment cycles). The patient achieved partial response confirmed by the computed tomography and the tumor marker CA19.9, CA50, and CA125 levels decreased significantly as an outcome of the treatment. The quality of life improved significantly. Major adverse events were fatigue, thrombocytopenia, leukopenia, and anemia, which were manageable with medication. The patient is still receiving treatment. Olaparib in the treatment of BRCA2-mutation-associated refractory advanced ICC patent is effective, and the adverse effects are tolerated. Large-scale studies should be conducted to further the adoption of genomic profiling, which may help clinicians identify suitable biomarkers for therapy of ICCs. A possible line of therapy is often extrapolated from case reports or small case series.